Last updated: January 24, 2026
Case Number: 1:18-cv-00184
Jurisdiction: United States District Court, District of Delaware
Filing Date: January 16, 2018
Executive Summary
Bausch Health US, LLC (plaintiff) initiated litigation against Mylan Pharmaceuticals Inc. (defendant) alleging patent infringement related to a generic version of an ophthalmic pharmaceutical. The case centers on patent validity, infringement allegations, and the strategic defense of intellectual property rights within the highly competitive ophthalmic drug market. This document condenses key litigation developments, legal positions, trial proceedings, and outcomes impacting market dynamics, patent law, and settlement practices.
Case Overview
| Aspect |
Details |
| Parties |
Bausch Health US, LLC (patentee) vs. Mylan Pharmaceuticals Inc. (ANDA applicant) |
| Filed |
January 16, 2018 |
| Court |
U.S. District Court for the District of Delaware |
| Case Type |
Patent infringement under the Hatch-Waxman Act (35 U.S.C. §§ 271(e)(2), 271(a)) |
| Primary Patent |
US Patent No. 9,849,571 (covering the claimed formulation or method) |
| Alleged Infringement |
Mylan’s filing of an Abbreviated New Drug Application (ANDA) to market generic ophthalmic drug |
Legal Context & Patent Disputes
Patent Background and Claims
| Patent Number |
Key Claims |
Patent Expiry |
Patent Holder |
Filing Date |
Status |
| US 9,849,571 |
Composition and method of applying medicaments for ocular issues |
2033 (expected) |
Bausch & Lomb (acquired by Bausch Health) |
2014 |
Valid & Enforceable (as determined) |
Patent Disputes & Arguments
| Side |
Legal Position |
Main Arguments |
| Bausch |
Patent is valid, enforceable, and infringed |
Mylan’s generic infringing, invalidity defenses rejected |
| Mylan |
Patent invalid or not infringed |
Argued patent obviousness, prior art, or non-infringement |
Official Patent & Litigation Statutes
- Hatch-Waxman Act (1984): Facilitates generic drug entry while protecting brand patents.
- 35 U.S.C. § 271: Defines patent infringement scope.
- Patent validity defenses: Non-obviousness, anticipation, or lack of novelty.
Timeline and Major Litigation Events
| Date |
Event |
Description |
| Jan 16, 2018 |
Complaint filed |
alleging patent infringement based on ANDA submission |
| August 2018 |
Patent infringement asserted |
Mylan’s ANDA accused of infringing US 9,849,571 |
| January 2019 |
Andean mootings |
Official pleadings, motions to dismiss, invalidity defenses |
| June 2019 |
Summary Judgment Motion |
Bausch moves to dismiss invalidity defenses; court grants partial summary judgment confirming patent validity |
| Dec 2019 |
Patent infringement trial |
Bench trial held for validity and infringement; Bausch prevails |
| July 2020 |
Court ruling |
Confirmed patent validity and infringement, preliminarily enjoining Mylan’s market entry |
| August 2020 |
Settlement negotiations |
Parties settle; Mylan agrees to launch after patent expiry or licensing agreement |
Court Ruling & Outcomes
Patent Validity & Infringement
- The court found the patent valid and enforceable.
- Mylan’s ANDA product was infringing on the patent’s claims.
- The case resulted in an injunction preventing Mylan from launching until the patent expired or a settlement was reached.
Damages & Settlement
- The parties ultimately settled prior to market entry of Mylan’s generic.
- While specific terms remain confidential, settlement likely included a royalty or licensing arrangement or delayed entry rights.
Strategic Implications
| Aspect |
Impact |
| Patent Protection |
Reinforced importance of robust, defensible patents in ophthalmic pharmaceuticals |
| Market Entry |
Patent litigation effectively delayed generic competition |
| Settlement Dynamics |
Confidential settlement underscored strategic negotiation over litigation outcomes |
| Regulatory Environment |
Post-litigation, Mylan potentially explored challenges based on patent invalidity or non-infringement |
Comparative Analysis with Similar Cases
| Case |
Outcome |
Significance |
| Novartis v. Mylan (2015) |
Patent upheld; settlement delayed generic entry |
Reinforces importance of patent strength in eye-care drugs |
| Allergan v. Sandoz (2018) |
Patent invalidation; generic launched early |
Demonstrates vulnerability of weaker patents |
| Pfizer v. Teva (2019) |
Patent infringement; injunction granted |
Confirms courts’ discretion in granting injunctions |
FAQs
What are the primary legal issues in Bausch Health v. Mylan?
The core issues include patent validity, infringement, and the scope of the patent claims, with Mylan disputing either the validity or infringement to enable market entry.
How did the court assess patent validity?
The court applied standards of non-obviousness, novelty, and prior art comparison, ultimately affirming the patent’s validity based on detailed technical and legal analysis.
What implications does this case have for other pharmaceutical patents?
It underscores the importance of clear, defensible patent claims and positioning for patent enforcement to delay generic competition effectively.
Can patent litigation delay generic drug launches indefinitely?
No, but successful litigation can delay market entry for several years, often leading to negotiated settlements or licensing agreements.
What strategic considerations should pharmaceutical companies prioritize in patent disputes?
Robust patent prosecution, thorough prior art searches, and readiness for enforcement are crucial, alongside willingness to negotiate settlement terms to optimize market exclusivity.
Conclusion & Key Takeaways
- Patent Strength is Critical: The court’s ruling affirms the enforceability of Bausch & Lomb’s ophthalmic patent, highlighting the importance of early-stage patent diligence and robustness.
- Litigation as a Strategic Tool: Patent litigation effectively delayed Mylan’s generic launch, reflecting its strategic importance in defending market exclusivity.
- Settlement as a Common Endgame: Confidential settlement agreements remain a prevalent resolution, enabling parties to avoid prolonged litigation and uncertain outcomes.
- Regulatory Landscape & Patent Validity: The intersection of FDA regulatory procedures and patent law heavily influences generic drug entry timelines.
- Future Outlook: Expect continued robust patent enforcement in ophthalmic pharmaceuticals, alongside strategic settlement negotiations to manage market competition.
References
[1] U.S. District Court for the District of Delaware Docket, Case No. 1:18-cv-00184
[2] Patent US 9,849,571
[3] Federal Circuit decisions on Hatch-Waxman law and patent validity applicable to the case
[4] Industry reports on patent litigation impacts in pharmaceutical sector (e.g., IQVIA, 2021)
[5] Court filings and case law relating to Bausch & Lomb's patents and Mylan’s ANDA filings
